- Home
- ZBRA vs INSM Comparison
ZBRA vs INSM Comparison
Compare ZBRA & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBRA
- INSM
- Stock Information
- Founded
- ZBRA 1969
- INSM 1988
- Country
- ZBRA United States
- INSM United States
- Employees
- ZBRA N/A
- INSM N/A
- Industry
- ZBRA Industrial Machinery/Components
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- ZBRA Industrials
- INSM Health Care
- Exchange
- ZBRA Nasdaq
- INSM Nasdaq
- Market Cap
- ZBRA 15.1B
- INSM 12.6B
- IPO Year
- ZBRA 1991
- INSM 2000
- Fundamental
- Price
- ZBRA $284.48
- INSM $70.65
- Analyst Decision
- ZBRA Buy
- INSM Strong Buy
- Analyst Count
- ZBRA 10
- INSM 17
- Target Price
- ZBRA $321.20
- INSM $95.93
- AVG Volume (30 Days)
- ZBRA 581.7K
- INSM 2.3M
- Earning Date
- ZBRA 04-29-2025
- INSM 05-08-2025
- Dividend Yield
- ZBRA N/A
- INSM N/A
- EPS Growth
- ZBRA 109.28
- INSM N/A
- EPS
- ZBRA 10.57
- INSM N/A
- Revenue
- ZBRA $5,114,000,000.00
- INSM $381,030,000.00
- Revenue This Year
- ZBRA $7.55
- INSM $29.15
- Revenue Next Year
- ZBRA $5.82
- INSM $115.02
- P/E Ratio
- ZBRA $27.42
- INSM N/A
- Revenue Growth
- ZBRA 17.45
- INSM 20.77
- 52 Week Low
- ZBRA $205.73
- INSM $53.69
- 52 Week High
- ZBRA $427.76
- INSM $84.91
- Technical
- Relative Strength Index (RSI)
- ZBRA 57.54
- INSM 55.25
- Support Level
- ZBRA $278.51
- INSM $65.56
- Resistance Level
- ZBRA $297.01
- INSM $68.74
- Average True Range (ATR)
- ZBRA 6.47
- INSM 2.32
- MACD
- ZBRA -0.46
- INSM 0.54
- Stochastic Oscillator
- ZBRA 42.05
- INSM 82.34
About ZBRA Zebra Technologies Corporation
Zebra Technologies is a leading provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.